With an injection of $11 million in Series A financing, a start-up called nference is hoping to shake up the life-sciences industry through its artificial intelligence (AI) technologies. Founded in 2013, the company aims to "synthesize the exponentially growing biomedical knowledge," using neural networks to glean insights from scientific literature, genomics, and real-world evidence, according to the announcement. To date, nference has raised $14 million in funding in pursuit of that goal, according to the start-up tracker Crunchbase. "Natural language is the connective fabric across all therapeutic areas and support functions of large pharmaceutical companies," Venky Soundararajan, PhD, the organization's founder and chief scientific officer, said in a statement, adding that nference's goals would change life sciences. "This presents a paradigm shift toward hypothesis-free scientific research and AI-augmented [research and development] R&D decision making."